Group 1 - The core point of the announcement is that Hainan Shuangcheng Pharmaceutical Co., Ltd. has received marketing authorization from the Australian Therapeutic Goods Administration (TGA) for its vasopressin injection [1][3]. - The vasopressin injection is indicated for the prevention and treatment of postoperative abdominal distension, clearing interference gas shadows in abdominal X-ray examinations, and treating diabetes insipidus [1][2]. - The product is developed by Par Pharmaceutical and was previously approved by the FDA in the United States on April 17, 2014 [2]. Group 2 - The global sales for the vasopressin injection are projected to be approximately $72 million in 2024, with the U.S. market accounting for about $46 million of that total [2]. - The approval for the Australian market is expected to positively impact the company's overseas market expansion and overall performance [3]. - There are uncertainties regarding the product's sales timeline, market size, and future expansion in Australia due to factors such as market demand fluctuations, policy changes, exchange rate volatility, and market competition [3].

Core Viewpoint - *ST Shuangcheng (002693.SZ) has recently received marketing authorization for its arginine vasopressin injection from the Australian Therapeutic Goods Administration (TGA) [1] Group 1: Company Developments - The company has obtained a significant regulatory approval for its arginine vasopressin injection, which is a critical step for market entry [1] - The product is available in a specification of 20 pressor units per 1 mL [1] Group 2: Market Insights - According to the Insight database, the global sales for arginine vasopressin injection are projected to reach approximately $72 million in 2024 [1] - The U.S. market is expected to contribute around $46 million to the total sales [1]